Cipla Limited
CIPLA
주식 순위
#1810
Cipla Limited, along with its associated entities, operates as a global... Cipla Limited, along with its associated entities, operates as a global pharmaceutical enterprise, specializing in the creation and distribution of a wide array of medicinal products. Its extensive portfolio includes both active pharmaceutical ingredients (APIs) and a diverse range of finished formulations, addressing numerous therapeutic areas such as cardiovascular diseases, metabolic disorders, HIV, respiratory conditions, urology, oncology, pediatric health, infectious diseases, critical care, hepatitis, women's health, ophthalmology, and neuropsychiatry. The company maintains a strong focus on respiratory treatments, offering various inhalers, nasal sprays, injectables, and biosimilars. Cipla has also forged significant partnerships, including a licensing arrangement with Merck & Co., Inc. for the manufacturing and commercialization of the investigational oral antiviral drug Molnupiravir, and a separate license agreement with Eli Lilly and Company for baricitinib, indicated for COVID-19. Furthermore, it collaborates with Dr. Reddy's Laboratories Ltd, Sun Pharmaceutical Industries Limited, Emcure Pharmaceuticals Limited, and Torrent Pharmaceuticals Limited for Molnupiravir's clinical trials. Established in 1935, Cipla's corporate headquarters are located in Mumbai, India.
주가
$14.61
마지막 동기화: 2026-10-19
시가총액
$11.81B
변동 (1일)
-0.11%
변동 (1년)
-21.65%
국가
IN
거래 Cipla Limited (CIPLA)
카테고리
Healthcare
Cipla Limited (CIPLA)의 P/S 비율
October 2026 기준 P/S 비율 TTM: 3.82
Cipla Limited의 최신 재무 보고서와 주가에 따르면 현재 P/S 비율(TTM)은 3.82입니다. 2024년 말 기준 P/S 비율은 4.74였습니다.
Cipla Limited의 P/S 비율 기록 (2004 ~ 2026)
매년 말 P/S 비율
| 연도 | P/S 비율 | 변화 |
|---|---|---|
| 2026 (TTM) | 3.82 | -10.80% |
| 2025 | 4.28 | -9.65% |
| 2024 | 4.74 | 47.08% |
| 2023 | 3.22 | -14.85% |
| 2022 | 3.78 | 10.05% |
| 2021 | 3.44 | 72.27% |
| 2020 | 2.00 | -23.06% |
| 2019 | 2.59 | -15.52% |
| 2018 | 3.07 | -7.69% |
| 2017 | 3.33 | 9.59% |
| 2016 | 3.03 | -39.81% |
| 2015 | 5.04 | 86.12% |
| 2014 | 2.71 | -27.40% |
| 2013 | 3.73 | 6.94% |
| 2012 | 3.49 | -98.05% |
| 2011 | 179.33 | 3,495.17% |
| 2010 | 4.99 | 44.67% |
| 2009 | 3.45 | -19.14% |
| 2008 | 4.26 | -20.21% |
| 2007 | 5.34 | -22.03% |
| 2006 | 6.85 | 94.90% |
| 2005 | 3.52 | -7.98% |
| 2004 | 3.82 | 0.00% |
유사 기업 또는 경쟁사의 P/S 비율
| 회사 | P/S 비율 | P/S 비율 차이 | 국가 |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| - | - |
JP
|
|
| - | - |
CH
|
|
| 7.06 | 84.88% |
IN
|
